natgillin/translations-raw huggingface dataset:
Continue to fill the syringe with the correct volume of the solvent for injection, as described in the text of figure 4 above. 
Nastavite puniti štrcaljku ispravnim volumenom otapala za injekciju, kako je opisano u tekstu iznad slike 4. Izvucite iglu štrcaljke iz bočice.
Common: Tachycardia, heart rate abnormal/irregular Vascular disorders 
Često: tahikardija, abnormalan/nepravilan rad srca
Withdraw the syringe from the vial. 
Izvucite štrcaljku iz bočice.
The syringe should be filled with a volume of air equal to the required volume of the solvent for injection and the air injected into the solvent vial to make it easier to withdraw the solvent. 
Štrcaljku treba napuniti volumenom zraka koji je jednak potrebnom volumenu otapala za injekciju i ubrizgati taj zrak u bočicu s otapalom da se olakša izvlačenje otapala.
Oral oestrogen administration increases the dose requirements in women. 
Kod primjene peroralnog estrogena u žena potrebna je veća doza.
Somatropin Biopartners should be administered subcutaneously at a concentration of 10 mg/mL. 
Somatropin Biopartners mora se primijeniti supkutano u koncentraciji od 10 mg/ml.
Infections and infestations Common: Herpes simplex 
Često: herpes simpleks
Vascular disorders Rare: hypertension* 
Rijetko: hipertenzija*
If you forget to use Somatropin Biopartners 
Ako ste zaboravili primijeniti Somatropin Biopartners
Talk to your doctor before using Somatropin Biopartners if you: - are an adult who has been treated with growth hormone during childhood: Your doctor will re-examine you for lack of growth hormone before restarting/continuing treatment; - have a hereditary disease called Prader-Willi syndrome: You should not be treated with this medicine unless you also have a lack of growth hormone; - have had a tumour: Your doctor will examine you frequently to ensure that the tumour has not come back; - have symptoms like severe and recurrent headache, visual changes, nausea and/or vomiting which may be due to increased pressure in the skull during growth hormone treatment; - suffer from an organic growth hormone deficiency (lack of growth hormone due to damage to the pituitary gland or the part of the brain called the hypothalamus) or decreased secretion of 
Obratite se svom liječniku prije nego primijenite Somatropin Biopartners ako: - ste odrasla osoba koja se liječila hormonom rasta tijekom djetinjstva: Liječnik će Vas ponovno pregledati na nedostatak hormona rasta prije ponovnog početka/nastavka liječenja; - imate nasljednu bolest koja se zove Prader-Willijev sindrom: Ne smijete se liječiti ovim lijekom osim ako nemate i nedostatak hormona rasta; - ako ste imali tumor: Liječnik će Vas često pregledavati kako bi osigurao da se tumor nije vratio; - imate simptome poput teške i ponavljajuće glavobolje, promjena vida, mučnine i/ili povraćanja, koji mogu biti posljedica povišenja tlaka u glavi tijekom liječenja hormonom rasta; - bolujete od organskog nedostatka hormona rasta (nedostatak hormona rasta zbog oštećenja hipofize ili dijela mozga koji se zove hipotalamus) ili smanjenog izlučivanja hormona hipofize: Liječnik će Vam provjeriti razine hormona nadbubrežne žlijezde (glukokortikoida), koji mogu zahtijevati prilagodbu prije nego što počne terapija hormonom rasta.
Insert the needle through the centre of the rubber stopper of the solvent vial and inject all of the air into the vial. 
Uvedite iglu kroz sredinu gumenog čepa na bočici s otapalom i ubrizgajte sav zrak u bočicu.
If you stop using Somatropin Biopartners 
Ako prestanete primjenjivati Somatropin Biopartners
Skin and subcutaneous tissue disorders Common: pigmentation disorder (1.1%) 
Često: poremećaj pigmentacije (1,1%)
Talk to your doctor before using Somatropin Biopartners if you: - have a hereditary disease called Prader-Willi syndrome: You should not be treated with this medicine unless you also have a lack of growth hormone; - have had a tumour: Your doctor will examine you frequently to ensure that the tumour has not come back; - have symptoms like severe and recurrent headache, visual changes, nausea and/or vomiting which may be due to increased pressure in the skull during growth hormone treatment; - suffer from an organic growth hormone deficiency (lack of growth hormone due to damage to the pituitary gland or the part of the brain called the hypothalamus) or decreased secretion of 
Obratite se svom liječniku prije nego primijenite Somatropin Biopartners ako: - imate nasljednu bolest koja se zove Prader-Willijev sindrom: Ne smijete se liječiti ovim lijekom osim ako nemate i nedostatak hormona rasta; - ako ste imali tumor: Liječnik će Vas često pregledavati kako bi osigurao da se tumor nije vratio: - imate simptome poput teške i ponavljajuće glavobolje, promjene vida, mučnine i/ili povraćanja, koji mogu biti posljedica povišenja tlaka u glavi tijekom liječenja hormonom rasta; - bolujete od organskog nedostatka hormona rasta (nedostatak hormona rasta zbog oštećenja hipofize ili dijela mozga koji se zove hipotalamus) ili smanjenog izlučivanja hormona hipofize: Liječnik će Vam provjeriti razine hormona nadbubrežne žlijezde (glukokortikoida), koji mogu zahtijevati prilagodbu prije nego što počne terapija hormonom rasta.
Clean the rubber stopper again with an unused alcohol swab. 
Ponovno očistite gumeni čep novom vaticom natopljenom alkoholom.
IGF-I SDS in the range of -1 to +1 and more than 1 SDS increase from Baseline Maintain 
IGF-I SDS u rasponu od -1 do +1 i porast više od 1 SDS od početne vrijednosti nema
Investigations Common: decreased blood cortisol (2.2%) 
Često: snižen kortizol u krvi (2,2%) Opis odabranih nuspojava
Hepatobiliary disorders Common: Hyperbilirubinaemia, cholecystitis, liver test abnormal 
Često: hiperbilirubinemija, kolecistitis, abnormalni rezultati jetrenih testova
The syringe should be held upright and gentle pressure applied to the plunger until a small drop of suspension appears at the end of the needle. 
Štrcaljku treba držati uspravno i nježno potiskivati klip sve dok se na vršku igle ne pojavi kapljica.
Gently tap the syringe to remove small air bubbles. 
Nježno kucnite po štrcaljki da biste uklonili mjehuriće zraka.
4 vials of 1.5 mL solvent 
4 bočice s 1,5 ml otapala
The powder should be homogenously suspended in the injection vehicle prior to administration. 
Prije primjene, prašak treba homogeno suspendirati u otapalu injekcije.
Use a 1 mL or 2 mL graduated syringe with a 19G or wider needle for withdrawing the solvent from its vial. 
Uporabite graduiranu štrcaljku od 1 ml ili 2 ml s iglom od 19G ili širom za izvlačenje otapala iz bočice.
Powder: sodium hyaluronate, egg phospholipids, sodium dihydrogen phosphate anhydrous, disodium phosphate anhydrous. 
Prašak: natrijev hijaluronat, fosfolipidi jaja, natrijev dihidrogenfosfat bezvodni, natrijev hidrogenfosfat bezvodni.
Use a 1 mL graduated syringe with a 19G or wider needle for withdrawing the solvent from its vial. 
Uporabite graduiranu štrcaljku od 1 ml s iglom od 19G ili širom za izvlačenje otapala iz bočice.
Powder and solvent for prolonged-release suspension for injection. 
Prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem.
Without touching the rubber top the vial should be swirled vigorously until the content is completely mixed. 
Bez dodirivanja gumenog vrha bočicu treba žustro mućkati kružnim pokretima dok se sav sadržaj ne promiješa.
Neoplasms benign, malignant and unspecified (including cysts and polyps) Common: Neoplasm progression (1 case of neoplasm progression in a female patient with a history of neurofibromatosis and radiation treatment), acrochordon, craniopharyngioma 
Često: napredovanje novotvorine (1 slučaj napredovanja novotvorine u bolesnice s anamnezom neurofibromatoze i radioterapije), viseći kožni fibrom, kraniofaringeom
To remove small air bubbles the syringe should be tapped gently. 
Da bi se uklonili mjehurići zraka, treba nježno kucnuti po štrcaljki.
Apply gentle pressure to the plunger until a small drop of suspension appears at the end of the needle. 
Nježno potisnite klip sve dok se na vršku igle ne pojavi kapljica suspenzije.
Common: Swelling face, acne, allergic dermatitis, hyperhidrosis, urticaria, rash Musculoskeletal and connective tissue disorders 
Često: otok lica, akne, alergijski dermatitis, hiperhidroza, urtikarija, osip
For other doses vials with 4 or 7 mg somatropin are available. 
Za druge doze dostupne su bočice s 4 ili 7 mg somatropina.
For other doses vials with 2 or 7 mg somatropin are available. 
Za druge doze dostupne su bočice s 2 ili 7 mg somatropina.
The 20-mg vial contains an overfill of somatropin powder to allow the withdrawal of up to 20 mg (1 mL suspension) of somatropin when reconstituted. 
Bočica s 20 mg sadrži nešto više somatropin praška kako bi se omogućilo izvlačenje do 20 mg (1 ml suspenzije) somatropina nakon rekonstitucije.
The somatropin in this medicinal product is synthesised in yeast (Saccharomyces cerevisiae). 
Somatropin u ovom lijeku sintetiziran je u kvascu
Antibodies 
Protutijela
Vigorously swirl the vial without touching the rubber top with your fingers until the content is completely mixed. 
Kružnim pokretima žustro vrtite sadržaj bočice sve dok se sav sadržaj potpuno ne pomiješa i pritom nemojte dodirivati gumeni vrh prstima.
For other doses vials with 2 or 4 mg somatropin are available. 
Za druge doze dostupne su bočice s 2 ili 4 mg somatropina.
Somatropin Biopartners 20 mg should be reconstituted with 1.2 mL solvent. 
Somatropin Biopartners 20 mg treba rekonstituirati s 1,2 ml otapala.
IGF-I SDS in the range of -1 to +1 and less than 1SDS increase from Baseline 
IGF-I SDS u rasponu od -1 to +1 i porast manji od 1 SDS od početne vrijednosti
Your doctor will stop your treatment with this medicine if there is evidence of cancerous growth; - if you are ill due to a serious heart or stomach operation; 
Vaš liječnik će zaustaviti liječenje ovim lijekom ako postoji dokaz rasta tumora; - ako ste bolesni zbog ozbiljne operacije na srcu ili želucu; - ako se liječite od više od jedne ozljede nakon ozbiljne nezgode; - ako iznenada razvijete ozbiljne tegobe s disanjem.
Gastrointestinal disorders Common: vomitting (1.1%), abdominal pain (1.1%) 
Često: povraćanje (1,1%), bol u trbuhu (1,1%)
Somatropin Biopartners is a powder and solvent for prolonged-release suspension for injection. 
Somatropin Biopartners je prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem.
The amino acid sequence of the active substance is identical to that of hGH of pituitary origin. 
Slijed aminokiselina u djelatnoj tvari istovjetan je onome hGH iz hipofize.
For children heavier than 20 kg, Somatropin Biopartners 20 mg powder and solvent for prolonged-release suspension for injection is available. 
Za djecu tjelesne težine veće od 20 kg, dostupan je Somatropin Biopartners 20 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem.
Due to the prolonged-release characteristics of this medicinal product peak levels of growth hormone can be expected approximately 15 hours after injection, see section 5.2. 
Zbog toga što je ovo lijek s produljenim oslobađanjem, vršne razine hormona rasta mogu se očekivati približno 15 sati nakon injekcije, vidjeti dio 5.2. Dugotrajno predoziranje može rezultirati znakovima i simptomima gigantizma i/ili akromegalije koji su sukladni poznatim učincima prekomjerne količine hGH.
Hold the syringe upright. 
Držite štrcaljku uspravno.
Put an adhesive plaster on the injection site. 
Mjesto injekcije prekrijte samoljepivim flasterom.
figure 
slika
Common: Haematuria, increased blood uric acid, increased blood creatinine Reproductive system and breast disorders 
Često: hematurija, povećana mokraćna kiselina u krvi, povećan kreatinin u krvi
To remove any bubbles, gently tap the syringe. 
Da biste uklonili eventualne mjehuriće, nježno kucnite po štrcaljki.
1 vial of powder and 1 vial of solvent. 
1 bočica praška i 1 bočica otapala.
One powder vial delivers 7 mg of somatropin (21 IU). 
Jedna bočica praška sadrži: 7 mg somatropina (21 IU).
Musculoskeletal and connective tissue disorders Common: arthralgia (1.1%), pain in extremities (5.1%) 
Često: artralgija (1,1%), bol u ekstremitetima (5,1%)*
One powder vial delivers 20 mg of somatropin (60 IU). 
Jedna bočica praška sadrži 20 mg somatropina (60 IU).
The vial should be turned upside down, with the syringe in and the tip of the needle should be placed in the solvent. 
Bočicu s uvedenom štrcaljkom treba okrenuti naopako, a vršak igle treba biti postavljen u otapalo.
- Somatropin Biopartners 7 mg: One vial of powder delivers 7 mg somatropin, corresponding to 21 IU. 
- Somatropin Biopartners 7 mg: Jedna bočica praška sadrži 7 mg somatropina, što odgovara 21 IU.
Reproductive system and breast disorders Very rare: gynaecomastia* 
Često: bolnost bradavica Manje često: ginekomastija*
After reconstitution, 1 mL of suspension contains 20 mg (20 mg/mL). 
Nakon pripreme, 1 ml suspenzije sadrži 20 mg (20 mg/ml).
The 10-mg vial contains an overfill of somatropin powder to allow the withdrawal of up to 10 mg (0.5 mL suspension) of somatropin when reconstituted. 
Bočica s 10 mg sadrži nešto više somatropin praška kako bi se omogućilo izvlačenje do 10 mg (0,5 ml suspenzije) somatropina nakon rekonstitucije.
For children up to 20 kg Somatropin Biopartners 10 mg powder and solvent for prolonged-release suspension for injection is available. 
Za djecu tjelesne težine do 20 kg dostupan je Somatropin Biopartners 10 mg prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem.
Powder and solvent for prolonged-release suspension for injection 1 vial of 10 mg powder 
Prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem 1 bočica s 10 mg praška
- Somatropin Biopartners 20 mg: One vial of powder delivers 20 mg somatropin, corresponding to 60 IU. 
- Somatropin Biopartners 20 mg: Jedna bočica praška sadrži 20 mg somatropina, što odgovara 60 IU.
After preparation, 1 mL of suspension contains 20 mg somatropin (20 mg/mL). 
Nakon pripreme, 1 ml suspenzije sadrži 20 mg somatropina (20 mg/ml).
MARKETING AUTHORISATION NUMBER(S) EU/1/13/849/006 1 vial of powder and 1 vial of solvent EU/1/13/849/007 4 vials of powder and 4 vials of solvent 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/13/849/006 1 bočica praška i 1 bočica otapala EU/1/13/849/007 4 bočice praška i 4 bočice otapala 13. BROJ SERIJE
Conversion from required dose to injection volume and vial strength Somatropin dose vials and solvent required for preparation of 
Pretvorba potrebne doze u volumen injekcije i jačinu bočice Doza somatropina (mg)
One powder vial delivers 10 mg of somatropin (30 IU). 
Jedna bočica praška sadrži: 10 mg somatropina(30 IU).
There is no relevant use of Somatropin Biopartners 7 mg in the paediatric population in the indication of long-term treatment of growth failure due to insufficient secretion of endogenous growth hormone. 
Nema relevantne primjene Somatropina Biopartners 7 mg u pedijatrijske populacije u indikaciji dugotrajnog liječenja zaostajanja u rastu zbog nedostatnog lučenja endogenog hormona rasta.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Solvent for Somatropin Biopartners 
NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA Otapalo za Somatropin Biopartners NAČIN PRIMJENE LIJEKA
MARKETING AUTHORISATION NUMBER(S) EU/1/13/849/004 1 vial of powder and 1 vial of solvent EU/1/13/849/005 4 vials of powder and 4 vials of solvent 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/13/849/004 1 bočica praška i 1 bočica otapala EU//1/13/849/005 4 bočice praška i 4 bočice otapala 13. BROJ SERIJE
Shelf-life after reconstitution with solvent 
Rok valjanosti nakon pripreme suspenzije s otapalom
There is no relevant use of Somatropin Biopartners 4 mg in the paediatric population in the indication of long-term treatment of growth failure due to insufficient secretion of endogenous growth hormone. 
Nema relevantne primjene Somatropina Biopartners 4 mg u pedijatrijske populacije u indikaciji dugotrajnog liječenja zaostajanja u rastu zbog nedostatnog lučenja endogenog hormona rasta.
One powder vial delivers 2 mg of somatropin (6 IU). 
Jedna bočica praška sadrži: 2 mg somatropina (6 IU).
- Somatropin Biopartners 10 mg: One vial of powder delivers 10 mg somatropin, corresponding to 30 IU. 
- Somatropin Biopartners 10 mg: Jedna bočica praška sadrži 10 mg somatropina, što odgovara 30 IU.
- Somatropin Biopartners 2 mg: One vial of powder delivers 2 mg somatropin, corresponding to 6 IU. 
- Somatropin Biopartners 2 mg: Jedna bočica praška sadrži 2 mg somatropina, što odgovara 6 IU.
None or -0.5 mg (all patients) 
održavati ili sniziti kliničkom statusu nema ili -0,5 mg (svi bolesnici)
Pack size of 1 vial of powder and 1 vial of solvent and 4 vials of powder and 4 vials of solvent. 
Veličina pakiranja od 1 bočice s praškom i 1 bočice s otapalom te 4 bočice s praškom i 4 bočice s otapalom.
Pack sizes of 1 vial of powder and 1 vial of solvent and 4 vials of powder and 4 vials of solvent. 
Veličine pakiranja od 1 bočice s praškom i 1 bočice s otapalom te 4 bočice s praškom i 4 bočice s otapalom.
- Somatropin Biopartners 4 mg: One vial of powder delivers 4 mg somatropin, corresponding to 12 IU. 
- Somatropin Biopartners 4 mg: Jedna bočica praška sadrži 4 mg somatropina, što odgovara 12 IU.
Powder and solvent for prolonged-release suspension for injection 4 vials of 7 mg powder 
Prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem 4 bočice s 7 mg praška
After reconstitution, 0.5 mL of suspension contains 10 mg (20 mg/mL). 
Nakon pripreme, 0,5 ml suspenzije sadrži 10 mg (20 mg/ml).
For adults 
I DOHVATA DJECE
There is no relevant use of Somatropin Biopartners 2 mg in the paediatric population in the indication of long-term treatment of growth failure due to insufficient secretion of endogenous growth hormone. 
Nema relevantne primjene Somatropina Biopartners 2 mg u pedijatrijske populacije u indikaciji dugotrajnog liječenja zaostajanja u rastu zbog nedostatnog lučenja endogenog hormona rasta.
The vial contains an overfill of somatropin powder to allow the withdrawal of up to 7 mg (0.7 mL suspension) of somatropin when reconstituted. 
Bočica sadrži nešto više somatropin praška kako bi se omogućilo izvlačenje do 7 mg (0,7 ml suspenzije) somatropina nakon rekonstitucije.
After reconstitution, 0.7 mL of suspension contains 7 mg (10 mg/mL). 
Nakon pripreme, 0,7 ml suspenzije sadrži 7 mg (10 mg/ml).
Immune system disorders Common: Formation of antibodies against growth hormone 
Često: stvaranje protutijela na hormon rasta
One powder vial delivers 4 mg of somatropin (12 IU). 
Jedna bočica praška sadrži: 4 mg somatropina(12 IU).
After preparation, 0.5 mL of suspension contains 10 mg somatropin (20 mg/mL). 
Nakon pripreme, 0,5 ml suspenzije sadrži 10 mg somatropina (20 mg/ml).
1.5 mL medium chain triglycerides 
SADRŽAJ PO TEŽINI, VOLUMENU ILI DOZNOJ JEDINICI LIJEKA 1,5 ml triglicerida srednje duljine lanca
The vial contains an overfill of somatropin powder to allow the withdrawal of up to 4 mg (0.4 mL suspension) of somatropin when reconstituted. 
Bočica sadrži nešto više somatropin praška kako bi se omogućilo izvlačenje do 4 mg (0,4 ml suspenzije) somatropina nakon rekonstitucije.
After reconstitution, 0.2 mL of suspension contains 2 mg (10 mg/mL). 
Nakon pripreme, 0,2 ml suspenzije sadrži 2 mg (10 mg/ml).
The vial contains an overfill of somatropin powder to allow the withdrawal of up to 2 mg (0.2 mL suspension) of somatropin when reconstituted. 
Bočica sadrži nešto više somatropin praška kako bi se omogućilo izvlačenje do 2 mg (0,2 ml suspenzije) somatropina nakon rekonstitucije.
4 vials of powder and 4 vials of solvent. 
4 bočice praška i 4 bočice otapala.
After reconstitution, 0.4 mL of suspension contains 4 mg (10 mg/mL). 
Nakon pripreme, 0,4 ml suspenzije sadrži 4 mg (10 mg/ml).
Turn the vial upside down, with the syringe inside and place the tip of the needle in the solvent as seen in figure 5. 
Okrenite bočicu s uvedenom štrcaljkom naopako i postavite vršak igle u otapalo kako je prikazano na slici 5. Polako izvucite potrebni volumen otapala.
After preparation, 0.7 mL of suspension contains 7 mg somatropin (10 mg/mL). 
Nakon pripreme, 0,7 ml suspenzije sadrži 7 mg somatropina (10 mg/ml).
Powder and solvent for prolonged-release suspension for injection 4 vials of 4 mg powder 
Prašak i otapalo za suspenziju za injekciju s produljenim oslobađanjem 4 bočice s 4 mg praška
Somatropin Biopartners 2 mg should be reconstituted with 0.4 mL solvent. 
Somatropin Biopartners 2 mg treba rekonstituirati s 0,4 ml otapala.
Somatropin Biopartners 4 mg should be reconstituted with 0.6 mL solvent. 
Somatropin Biopartners 4 mg treba rekonstituirati s 0,6 ml otapala.
Somatropin Biopartners 10 mg should be reconstituted with 0.7 mL solvent. 
Somatropin Biopartners 10 mg treba rekonstituirati s 0,7 ml otapala.
After preparation, 0.4 mL of suspension contains 4 mg somatropin (10 mg/mL). 
Nakon pripreme, 0,4 ml suspenzije sadrži 4 mg somatropina (10 mg/ml).
Somatropin Biopartners 7 mg should be reconstituted with 0.9 mL solvent. 
Somatropin Biopartners 7 mg treba rekonstituirati s 0,9 ml otapala.
Pack size of 4 vials of powder and 4 vials of solvent. 
Veličina pakiranja od 4 bočice s praškom i 4 bočice s otapalom.
- Somatropin Biopartners 20 mg: 20 mg (60 IU) somatropin as powder in a glass vial closed with a rubber stopper (butyl) and a green flip-off cap (aluminium and plastic) and 1.5 mL solvent (medium chain triglycerides) in glass vial with a rubber stopper (butyl). 
- Somatropin Biopartners 20 mg: 20 mg (60 IU) somatropina u prašku u staklenoj bočici zatvorenoj gumenim čepom (butil) i zelenim „flip-off“ poklopcem (aluminij i plastika) i 1,5 ml otapala (trigliceridi srednje duljine lanca) u staklenoj bočici s gumenim (butilnim) čepom.
Sodium hyaluronate 
Za odrasle somatropin
After preparation, 0.2 mL of suspension contains 2 mg somatropin (10 mg/mL). 
Nakon pripreme, 0,2 ml suspenzije sadrži 2 mg somatropina (10 mg/ml).
None 
DRUGO
Each vial of powder delivers 20 mg somatropin; each vial of solvent contains 1.5 mL liquid. 
Jedna bočica s praškom sadrži 20 mg somatropina; jedna bočica otapala sadrži 1,5 ml tekućine.
Sodium dihydrogen phosphate anhydrous Disodium phosphate anhydrous. 
Prašak: natrijev hijaluronat fosfolipidi jaja natrijev dihidrogenfosfat, bezvodni natrijev hidrogenfosfat, bezvodni.
- Somatropin Biopartners 4 mg: 4 mg (12 IU) somatropin as powder in a glass vial closed with a rubber stopper (butyl) and a pink flip-off cap (aluminium and plastic) and 1.5 mL solvent (medium chain triglycerides) in glass vial with a rubber stopper (butyl). 
- Somatropin Biopartners 4 mg: 4 mg (12 IU) somatropina u prašku u staklenoj bočici zatvorenoj gumenim čepom (butil) i ružičastim „flip-off“ poklopcem (aluminij i plastika) i 1,5 ml otapala (trigliceridi srednje duljine lanca) u staklenoj bočici s gumenim (butilnim) čepom.
- Somatropin Biopartners 2 mg: 2 mg (6 IU) somatropin as powder in a glass vial closed with a rubber stopper (butyl) and a yellow flip-off cap (aluminium and plastic) and 1.5 mL solvent (medium chain triglycerides) in a glass vial with a rubber stopper (butyl). 
- Somatropin Biopartners 2 mg: 2 mg (6 IU) somatropina u prašku u staklenoj bočici zatvorenoj gumenim čepom (butil) i žutim „flip-off“ poklopcem (aluminij i plastika) i 1,5 ml otapala (trigliceridi srednje duljine lanca) u staklenoj bočici s gumenim (butilnim) čepom.
- Somatropin Biopartners 7 mg: 7 mg (21 IU) somatropin as powder in a glass vial closed with a rubber stopper (butyl) and a light-blue flip-off cap (aluminium and plastic) and 1.5 mL solvent (medium chain triglycerides) in glass vial with a rubber stopper (butyl). 
- Somatropin Biopartners 7 mg: 7 mg (21 IU) somatropina u prašku u staklenoj bočici zatvorenoj gumenim čepom (butil) i svijetloplavim „flip-off“ poklopcem (aluminij i plastika) i 1,5 ml otapala (trigliceridi srednje duljine lanca) u staklenoj bočici s gumenim (butilnim) čepom.